UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists

PloS one, 2016-12, Vol.11 (12), p.e0164485-e0164485

2016

Volltextzugriff (PDF)

Efficient expression of functional human coagulation factor IX in stably-transfected Drosophila melanogaster S2 cells; comparison with the mammalian CHO system

Biotechnology letters, 2016-10, Vol.38 (10), p.1691-1698

2016

Volltextzugriff (PDF)

Effect of prepropeptide replacement on γ-carboxylation and activity of recombinant coagulation factor IX

Biotechnology letters, 2022-08, Vol.44 (8), p.975-984

2022

Volltextzugriff (PDF)

Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line

Biotechnology letters, 2015-09, Vol.37 (9), p.1773-1781

2015

Volltextzugriff (PDF)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Nature communications, 2017-09, Vol.8 (1), p.528-10, Article 528

2017

Volltextzugriff (PDF)

Coagulopathy after hemorrhagic traumatic brain injury, an observational study of the incidence and prognosis

Acta neurochirurgica, 2020-02, Vol.162 (2), p.329-336

2020

Volltextzugriff (PDF)

Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors

Toxicology in vitro, 2019-03, Vol.55, p.62-74

2019

Volltextzugriff (PDF)

Lipid levels and risk of venous thrombosis: results from the MEGA-study

European journal of epidemiology, 2017-08, Vol.32 (8), p.669-681

2017

Volltextzugriff (PDF)

Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations

Blood, 2009-07, Vol.114 (3), p.686-692

2009

Volltextzugriff (PDF)

Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom

Toxicology in vitro, 2019-08, Vol.58, p.97-109

2019

Volltextzugriff (PDF)

Pharmacological Characterisation of Pseudocerastes and Eristicophis Viper Venoms Reveal Anticancer (Melanoma) Properties and a Potentially Novel Mode of Fibrinogenolysis

International journal of molecular sciences, 2021-07, Vol.22 (13), p.6896

2021

Volltextzugriff (PDF)

Improved activity and expression of recombinant human factor IX by propeptide engineering

Daru, 2019-12, Vol.27 (2), p.653-660

2019

Volltextzugriff (PDF)

Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding

Journal of thrombosis and haemostasis, 2019-08, Vol.17 (8), p.1229-1239

2019

Volltextzugriff (PDF)

Clinical implications of differential antivenom efficacy in neutralising coagulotoxicity produced by venoms from species within the arboreal viperid snake genus Trimeresurus

Toxicology letters, 2019-11, Vol.316, p.35-48

2019

Volltextzugriff (PDF)

Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme

Biotechnology progress, 2012-01, Vol.28 (1), p.45-51

2012

Volltextzugriff (PDF)

Blood coagulation factor IX: structural insights impacting hemophilia B therapy

Blood, 2024-07

2024

Volltextzugriff (PDF)

Erratum to: Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line

Biotechnology letters, 2015-10, Vol.37 (10), p.2097-2097

2015

Volltextzugriff (PDF)

Crippling down factor IX for therapeutic gain

Journal of thrombosis and haemostasis, 2023-12, Vol.21 (12), p.3287-3291

2023

Volltextzugriff (PDF)

Russell’s viper venom: from diagnostic to bypassing agent for hemophilia?

Journal of thrombosis and haemostasis, 2023-06, Vol.21 (6), p.1429-1431

2023

Volltextzugriff (PDF)

Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies

Seminars in thrombosis and hemostasis, 2020-11, Vol.46 (8), p.986-998

2020

Volltextzugriff (PDF)

Clinical implications of coagulotoxic variations in Mamushi (Viperidae: Gloydius) snake venoms

Comparative biochemistry and physiology. Toxicology & pharmacology, 2019-11, Vol.225, p.108567-108567, Article 108567

2019

Volltextzugriff (PDF)

Enhanced functional recombinant factor IX production by human embryonic kidney cells engineered to overexpress VKORC1

Biotechnology progress, 2020-03, Vol.36 (2), p.e2938-n/a

2020

Volltextzugriff (PDF)

Vitamin K therapy to reduce bleeding

Blood, 2020-08, Vol.136 (7), p.780-782

2020

Volltextzugriff (PDF)

Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors

Journal of thrombosis and haemostasis, 2024-08, Vol.22 (8), p.2211-2226

2024

Volltextzugriff (PDF)

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma

Journal of thrombosis and haemostasis, 2023-06, Vol.21 (6), p.1466-1477

2023

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists

Efficient expression of functional human coagulation factor IX in stably-transfected Drosophila melanogaster S2 cells; comparison with the mammalian CHO system

Effect of prepropeptide replacement on γ-carboxylation and activity of recombinant coagulation factor IX

Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Coagulopathy after hemorrhagic traumatic brain injury, an observational study of the incidence and prognosis

Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors

Lipid levels and risk of venous thrombosis: results from the MEGA-study

Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations

Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom

Pharmacological Characterisation of Pseudocerastes and Eristicophis Viper Venoms Reveal Anticancer (Melanoma) Properties and a Potentially Novel Mode of Fibrinogenolysis

Improved activity and expression of recombinant human factor IX by propeptide engineering

Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding

Clinical implications of differential antivenom efficacy in neutralising coagulotoxicity produced by venoms from species within the arboreal viperid snake genus Trimeresurus

Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme

Blood coagulation factor IX: structural insights impacting hemophilia B therapy

Erratum to: Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line

Crippling down factor IX for therapeutic gain

Russell’s viper venom: from diagnostic to bypassing agent for hemophilia?

Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies

Clinical implications of coagulotoxic variations in Mamushi (Viperidae: Gloydius) snake venoms

Enhanced functional recombinant factor IX production by human embryonic kidney cells engineered to overexpress VKORC1

Vitamin K therapy to reduce bleeding

Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma

Suchergebnisse filtern